Published in Eur J Clin Microbiol Infect Dis on November 14, 2009
Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev (2010) 2.66
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc (2011) 1.89
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infect Dis (2015) 1.34
Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother (2014) 1.19
Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria. Microbiol Insights (2016) 1.13
High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (2012) 1.08
ε/ζ systems: their role in resistance, virulence, and their potential for antibiotic development. J Mol Med (Berl) (2011) 1.04
In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae. J Antimicrob Chemother (2014) 1.03
'Old' antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis (2012) 1.02
High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother (2014) 0.96
Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis (2011) 0.93
Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob Agents Chemother (2011) 0.92
Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2010) 0.88
Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats. Antimicrob Agents Chemother (2014) 0.81
Whole-genome sequencing reveals clonal expansion of multiresistant Staphylococcus haemolyticus in European hospitals. J Antimicrob Chemother (2014) 0.81
Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model. Antimicrob Agents Chemother (2013) 0.81
Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2015) 0.80
Fosfomycin: Uses and potentialities in veterinary medicine. Open Vet J (2014) 0.77
Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. Can J Infect Dis Med Microbiol (2016) 0.77
Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. BMJ Open (2015) 0.76
Bacillithiol: a key protective thiol in Staphylococcus aureus. Expert Rev Anti Infect Ther (2015) 0.75
Fosfomycin antimicrobial prophylaxis for transrectal ultrasound-guided biopsy of the prostate: A prospective randomised study. Arab J Urol (2016) 0.75
Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario. Can J Infect Dis Med Microbiol (2017) 0.75
Penetration of fosfomycin into IPEC-J2 cells in the presence or absence of deoxynivalenol. PLoS One (2013) 0.75
Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats. Antimicrob Agents Chemother (2014) 0.75
Antibiotics for Gram-negative infections. Einstein (Sao Paulo) (2015) 0.75
Fosfomycin induced structural change in fosfomycin resistance kinases FomA: molecular dynamics and molecular docking studies. J Mol Model (2014) 0.75
The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci (1974) 7.21
Glycerol dissimilation and its regulation in bacteria. Annu Rev Microbiol (1976) 5.78
Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet (1996) 4.07
Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science (1969) 3.89
Isolation and characterization of a phosphonomycin-resistant mutant of Escherichia coli K-12. J Bacteriol (1972) 3.38
Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli. J Bacteriol (1973) 2.54
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother (2003) 1.89
Phosphonomycin: structure and synthesis. Science (1969) 1.87
Plasmid-determined resistance to fosfomycin in Serratia marcescens. Antimicrob Agents Chemother (1980) 1.80
Cloning and sequencing of Escherichia coli murZ and purification of its product, a UDP-N-acetylglucosamine enolpyruvyl transferase. J Bacteriol (1992) 1.59
International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother (1983) 1.52
Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect (2005) 1.50
Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium. J Bacteriol (1976) 1.48
Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster. Chem Biol (2006) 1.47
Purification of a glutathione S-transferase that mediates fosfomycin resistance in bacteria. Antimicrob Agents Chemother (1990) 1.44
Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents (2007) 1.44
Plasmid-encoded fosfomycin resistance. Antimicrob Agents Chemother (1991) 1.39
Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother (1993) 1.39
In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin. Antimicrob Agents Chemother (1986) 1.35
Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from Mycobacterium tuberculosis. Microbiology (1999) 1.33
In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. Antimicrob Agents Chemother (1989) 1.33
Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria. Antimicrob Agents Chemother (1988) 1.31
Nucleotide sequence of the fosB gene conferring fosfomycin resistance in Staphylococcus epidermidis. FEMS Microbiol Lett (1990) 1.30
In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis (2007) 1.28
In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother (2001) 1.24
In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother (2006) 1.23
Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother (2005) 1.22
In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983 to 1985. Antimicrob Agents Chemother (1990) 1.21
Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother (1997) 1.20
Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother (2000) 1.19
Pharmacokinetics of phosphonomycin in Man. I. Intravenous administration. J Pharm Sci (1971) 1.18
Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1986) 1.18
Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy (1997) 1.18
Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob Agents Chemother (1999) 1.17
Fosfomycin: Laboratory studies. Chemotherapy (1977) 1.17
Effect of combination of oxacillin and non-beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (1994) 1.15
High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother (2009) 1.14
In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents (2003) 1.11
In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother (2004) 1.11
Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain. Rev Esp Quimioter (2007) 1.07
In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1985) 1.05
Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K--12. J Antibiot (Tokyo) (1978) 1.04
Plasmid-mediated fosfomycin resistance is due to enzymatic modification of the antibiotic. Antimicrob Agents Chemother (1985) 1.01
In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother (1999) 1.01
In vitro susceptibility of community-acquired urinary tract pathogens to commonly used antimicrobial agents in Spain: a comparative multicenter study (2002-2004). J Chemother (2007) 1.00
Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother (2006) 1.00
Cloning and molecular epidemiology of plasmid-determined fosfomycin resistance. Antimicrob Agents Chemother (1986) 0.99
Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? J Antimicrob Chemother (2008) 0.98
Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection (1985) 0.98
Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1988) 0.98
Pharmacokinetics of fosfomycin. Chemotherapy (1977) 0.97
Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis (2008) 0.97
Antimicrobial activity of fosfomycin in vitro. J Antimicrob Chemother (1983) 0.97
Clinical pharmacology and in vitro activity of phosphonomycin. Antimicrob Agents Chemother (Bethesda) (1969) 0.97
Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate. Antimicrob Agents Chemother (1995) 0.96
Characterization of staphylococcal plasmids hybridizing with the fosfomycin resistance gene fosB. FEMS Microbiol Lett (1991) 0.96
In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter (2006) 0.95
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros (2003) 0.95
Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother (2003) 0.95
Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother (2003) 0.95
Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection (1988) 0.95
Pharmacokinetic aspects of cerebrospinal fluid penetration of fosfomycin. Int J Clin Pharmacol Res (1985) 0.93
Plasmid-mediated resistance to fosfomycin in Staphylococcus epidermidis. FEMS Microbiol Lett (1989) 0.91
Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis. J Antimicrob Chemother (1988) 0.91
Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother (2004) 0.90
Pharmacokinetic profile of fosfomycin trometamol. Chemotherapy (1993) 0.90
Adjuvant fosfomycin medication in chronic osteomyelitis. Infection (1989) 0.89
Novel Fosfomycin resistance of Pseudomonas aeruginosa clinical isolates recovered in Japan in 1996. Antimicrob Agents Chemother (2000) 0.88
Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa. Chemotherapy (2007) 0.88
The efficacy of a hydroxyapatite composite as a biodegradable antibiotic delivery system. Clin Orthop Relat Res (2004) 0.88
Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother (1999) 0.87
[Fosfomycin]. Rev Esp Quimioter (2003) 0.87
Fosfomycin trometamol versus amoxycillin--single-dose multicenter study of urinary tract infections. Chemotherapy (1990) 0.86
In-vitro activity of imipenem combined with beta-lactam antibiotics for methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (1991) 0.86
Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin. J Chemother (2005) 0.86
Pharmacodynamics of phosphonomycin after oral administration in man. Antimicrob Agents Chemother (Bethesda) (1969) 0.84
Experimental endocarditis and fosfomycin. Drugs Exp Clin Res (1985) 0.84
Fosfomycin and plasmidic resistance. Chemotherapy (1977) 0.84
Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1987) 0.84
In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis (2002) 0.84
The trometamol salt of fosfomycin: microbiological evaluation. Eur Urol (1987) 0.83
[Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006?]. Pathol Biol (Paris) (2006) 0.83
In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagn Microbiol Infect Dis (1992) 0.81
Bactericidal activity of cefotaxime and fosfomycin in cerebrospinal fluid during the treatment of rabbit meningitis experimentally induced by methicillin-resistant Staphylococcus aureus. Infection (1985) 0.80
[Perioperative preventive antibiotic treatment with fosfomycin in heart surgery: serum kinetics in extracorporeal circulation and determination of concentration in heart valve tissue]. Z Kardiol (1990) 0.80
Fosfomycin in Osteomyelitis. Chemotherapy (1976) 0.79
Pharmacokinetic comparison between fosfomycin and other phosphonic acid derivatives. Chemotherapy (1990) 0.79
Immunomodulatory effects of fosfomycin in an endotoxin model in human blood. J Antimicrob Chemother (2006) 0.78
In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1996) 0.78
Determination of fosfomycin in pus by capillary zone electrophoresis. J Chromatogr A (2005) 0.78
Serum and lung tissue levels of fosfomycin in humans. Int J Clin Pharmacol Ther Toxicol (1980) 0.77
Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J Antimicrob Chemother (2006) 0.77
Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci. Eur J Clin Microbiol Infect Dis (1997) 0.77
Introducing fosfomycin for surgical prophylaxis--emergence of resistance in aerobic faecal gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures. Scand J Infect Dis (1993) 0.77
Ocular penetration kinetics of fosfomycin administered as a one-hour infusion. Eur J Ophthalmol (1996) 0.77
Pharmacokinetics of disodium-fosfomycin in mongrel dogs. Res Vet Sci (2007) 0.77
[Critical study on methods for determining antibiotic tissue levels in humans (author's transl)]. Arzneimittelforschung (1980) 0.77
Synergism between cefotaxime and fosfomycin in the therapy of methicillin and gentamicin resistant Staphylococcus aureus infection in rabbits. Eur J Clin Microbiol Infect Dis (1990) 0.76
Fosfomycin/metronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective colorectal surgery. A randomised double-blind multicentre trial in 517 patients. Eur J Surg (1992) 0.76
InterProScan: protein domains identifier. Nucleic Acids Res (2005) 18.82
Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med (1993) 2.62
Aiolos regulates B cell activation and maturation to effector state. Immunity (1998) 2.24
Formation of disulphide-linked mu 2 omega 2 tetramers in pre-B cells by the 18K omega-immunoglobulin light chain. Nature (1987) 2.09
The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21. Immunity (2001) 2.04
The Mac-2 antigen is a galactose-specific lectin that binds IgE. J Exp Med (1989) 1.98
Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med (2003) 1.87
Nuclear factor kappa B is required for the development of marginal zone B lymphocytes. J Exp Med (2000) 1.48
Vitamin D, calcium, and epidermal differentiation. Endocr Rev (1993) 1.45
Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci U S A (1994) 1.45
The omega and iota surrogate immunoglobulin light chains. Curr Top Microbiol Immunol (1988) 1.43
Sterno-induced methanol toxicity and visual recovery after prompt hemodialysis. Case report. Arch Ophthalmol (1989) 1.38
Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro. Growth Factors (1998) 1.32
Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect Immun (2001) 1.29
A solid-phase sandwich radioimmunoassay for Entamoeba histolytica proteins and the detection of circulating antigens in amoebiasis. Gastroenterology (1982) 1.29
Breast gangrene in an HIV-positive patient. Ann R Coll Surg Engl (2009) 1.25
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia (2011) 1.24
Direct isolation of Francisella spp. from environmental samples. Lett Appl Microbiol (2009) 1.23
The major histocompatibility complex class I antigen-binding protein p88 is the product of the calnexin gene. Proc Natl Acad Sci U S A (1992) 1.22
Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos (2007) 1.20
Regulation of nuclear localization and transcriptional activity of TFII-I by Bruton's tyrosine kinase. Mol Cell Biol (1999) 1.19
An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele. Proc Natl Acad Sci U S A (1996) 1.19
Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother (2000) 1.19
Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem (1991) 1.17
Massive liver replacement by transplanted hepatocytes in the absence of exogenous growth stimuli in rats treated with retrorsine. Am J Pathol (2001) 1.17
Complete evulsion of the globe and optic nerve. Br J Ophthalmol (1987) 1.17
Fibrinogen cleavage by the Streptococcus pyogenes extracellular cysteine protease and generation of antibodies that inhibit enzyme proteolytic activity. Infect Immun (1999) 1.14
Changes in calcium responsiveness and handling during keratinocyte differentiation. Potential role of the calcium receptor. J Clin Invest (1996) 1.13
Hypokalemic quadriparesis in Sjogren syndrome. Indian J Nephrol (2011) 1.13
Impact of plasma protein binding on antimicrobial activity using time-killing curves. J Antimicrob Chemother (2004) 1.13
The omega/lambda 5 surrogate immunoglobulin light chain is expressed on the surface of transitional B lymphocytes in murine bone marrow. J Exp Med (1991) 1.11
A growth-constrained environment drives tumor progression invivo. Proc Natl Acad Sci U S A (2001) 1.11
The calcium sensing receptor and its alternatively spliced form in keratinocyte differentiation. J Biol Chem (1998) 1.09
Rickettsial infections in South India - how to spot the spotted fever. Indian Pediatr (2001) 1.09
Transcapillary insulin transfer in human skeletal muscle. Eur J Clin Invest (2003) 1.08
Molecular cloning of a human macrophage lectin specific for galactose. Proc Natl Acad Sci U S A (1990) 1.08
Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun (2012) 1.08
Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun (2000) 1.08
Bacterial profile of sepsis in a neonatal unit in south India. Indian Pediatr (1998) 1.07
Sperm acrosome status and sperm antibodies in infertility. J Urol (1998) 1.07
Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease. Gut (1998) 1.05
Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother (1999) 1.04
Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology (1989) 1.04
Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function. Arch Dermatol Res (1996) 1.04
Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother (2003) 1.03
1,25-Dihydroxyvitamin D3 potentiates the keratinocyte response to calcium. J Biol Chem (1994) 1.00
A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother (2000) 0.99
Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome. Ann Ophthalmol (1988) 0.98
Accelerated emigration of B lymphocytes in the Xid mouse. J Immunol (1999) 0.98
Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A (2000) 0.97
Nonoperative management of pneumatosis intestinalis and pneumoperitoneum in a patient with acute lymphoblastic leukemia: case report and review of the literature. Eur J Pediatr Surg (2010) 0.97
Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy. Allergy (2013) 0.97
Variants in the gene encoding C3 are associated with asthma and related phenotypes among African Caribbean families. Genes Immun (2006) 0.96
Radiolabeled polymerase chain reaction assay for detection of ras oncogene point mutations in tumors. Clin Chem (1994) 0.96
Tumor necrosis factor-alpha regulation of 1,25-dihydroxyvitamin D production by human keratinocytes. Endocrinology (1991) 0.96
Protein kinase C-associated kinase (PKK), a novel membrane-associated, ankyrin repeat-containing protein kinase. J Biol Chem (2001) 0.95
Tetrameric cell-surface MHC class I molecules. Nature (1992) 0.95
Production of biologically active fragments of parathyroid hormone by isolated Kupffer cells. J Biol Chem (1986) 0.93
Bilateral progressive essential iris atrophy and keratoconus with coincident features of posterior polymorphous dystrophy: a case report and proposed pathogenesis. Cornea (1992) 0.92
Paracrine effects of angiotensin-converting-enzyme- and angiotensin-II-receptor- inhibition on transcapillary glucose transport in humans. Life Sci (2000) 0.92
Tyrosine phosphorylation of Blk and Fyn Src homology 2 domain-binding proteins occurs in response to antigen-receptor ligation in B cells and constitutively in pre-B cells. Proc Natl Acad Sci U S A (1994) 0.91
Association of activated phosphatidylinositol 3-kinase with p120cbl in antigen receptor-ligated B cells. J Biol Chem (1995) 0.91
CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology (2007) 0.90
Analysis of plasma and peritoneal fluid concentrations of daptomycin in a patient with Enterococcus faecium peritonitis. Int J Antimicrob Agents (2008) 0.89
Granulocytic sarcoma of the head and neck: a case report. Am J Otolaryngol (2001) 0.89
Endoscopic KTP-532 laser assisted diverticulotomy for Zenker's diverticulum. Indian J Otolaryngol Head Neck Surg (2005) 0.87
Gastrointestinal nematode infection interferes with experimental allergic airway inflammation but not atopic dermatitis. Clin Exp Allergy (2009) 0.87
The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus. Vaccine (1994) 0.87
Accelerated proteasomal degradation of membrane Ig heavy chains. J Immunol (2000) 0.86
Electrocardiographical case. A man found unconscious. Singapore Med J (2006) 0.85
Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. J Antimicrob Chemother (2005) 0.85
The SH2 domains of Src family kinases associate with Syk. J Biol Chem (1995) 0.85
Induction of pneumococcal polysaccharide-specific mucosal immune responses by oral immunization. Vaccine (1996) 0.85
Endogenous prostaglandin E2 modulates calcium-induced differentiation in human skin keratinocytes. Prostaglandins Leukot Essent Fatty Acids (1993) 0.84
Surface transport and internalization of the membrane IgM H chain in the absence of the Mb-1 and B29 proteins. J Immunol (1993) 0.84
Squamous carcinoma cell lines produce 1,25 dihydroxyvitamin D, but fail to respond to its prodifferentiating effect. J Invest Dermatol (1991) 0.84
The cellular basis of the immune response to conjugate vaccines. Contrib Microbiol Immunol (1989) 0.84
Rhinofacial zygomycosis caused by conidiobolus coronatus. Indian J Otolaryngol Head Neck Surg (2004) 0.84
Effects of ATP, vanadate, and molybdate on cathepsin D-catalyzed proteolysis. J Biol Chem (1985) 0.83
Neurohydatidosis. Australas Radiol (2007) 0.83
Role of KTP-532 laser in management of oral submucous fibrosis. J Laryngol Otol (2008) 0.83
Synthetic peptide representing a T-cell epitope of CRM197 substitutes as carrier molecule in a Haemophilus influenzae type B (Hib) conjugate vaccine. Adv Exp Med Biol (1989) 0.83
Protein-protein conjugation on a lectin matrix. Biochem Biophys Res Commun (1977) 0.83
Distinct intracellular fates of membrane and secretory immunoglobulin heavy chains in a pre-B cell line. J Cell Biol (1991) 0.83
Critical density for protein-protein monoconjugation on a polysaccharide matrix. Biochim Biophys Acta (1979) 0.82
Affinity immobilisation and "negative" crosslinking: a probe for tertiary and quaternary protein structure. J Mol Biol (1979) 0.82
Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis. Ann Oncol (2009) 0.82
Monoconjugate enzyme linked immunoassay. FEBS Lett (1978) 0.82
Plasma pharmacokinetics of desmopressin following sublingual administration: an exploratory dose-escalation study in healthy male volunteers. Int J Clin Pharmacol Ther (2006) 0.81
Inhibition of caspase activity prevents anti-IgM induced apoptosis but not ceramide generation in WEHI 231 B cells. Mol Immunol (1998) 0.80
Squamous carcinoma cell lines fail to respond to 1,25-Dihydroxyvitamin D despite normal levels of the vitamin D receptor. J Invest Dermatol (1996) 0.80
ATP activation of parathyroid hormone cleavage catalyzed by cathepsin D from bovine kidney. J Biol Chem (1983) 0.80
Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Int J Clin Pharmacol Ther (2011) 0.80
Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of 1,25-dihydroxyvitamin D. J Invest Dermatol (1993) 0.80
Direct hyperplasia does not enhance the kinetics of liver repopulation in a new model of hepatocyte transplantation in the rat. J Hepatol (1999) 0.80
Effect of exercise on transdermal nicotine release in healthy habitual smokers. Int J Clin Pharmacol Ther (2005) 0.79
The binding of chondroitin 6-sulfate to plasma low density lipoprotein. Biochim Biophys Acta (1981) 0.79
Sulfated glycosaminoglycans synthesized by fibroblast, smooth muscle and endothelium-like cells grown in culture. Cell Differ (1983) 0.78
Nondysenteric intestinal amebiasis. Colonic morphology and search for Entamoeba histolytica adherence and invasion. Dig Dis Sci (1989) 0.78
Effects of streptozotocin-induced diabetes on neuroendocrine responses to ovariectomy and estrogen replacement in female rats. Neuroendocrinology (1993) 0.78